PUBLICATIONS

Key Research Articles


2017

Goldstein I, Paakinaho V, Baek S, Sung M, Hager GL. Synergistic Gene Expression During the Acute Phase Response is Characterized by Transcription Factor Assisted Loading. Nat Commun. 2017 Nov 29;8(1):1849.
 

Baek S*, Goldstein I*, Hager GL. Bivariate Genomic Footprinting Detects Changes in Transcription Factor Activity. Cell Rep. 2017 May 23;19(8):1710-1722. 
 

Goldstein I, Baek S, Presman DM, Paakinaho V, Swinstead EE, Hager GL. Transcription factor assisted loading and enhancer dynamics dictate the hepatic fasting response. Genome Res. 2017 Mar;27(3):427-439.

Key Review Articles

2017

Goldstein I, Hager GL. The three D's of transcription activation by glucagon - direct, delayed and dynamic. Endocrinology. 2017 Oct 25.
 

Goldstein I, Hager GL. Dynamic enhancer function in the chromatin context. Wiley Interdiscip Rev Syst Biol Med. 2017 May 22. 
 

2015

Goldstein I, Hager GL. Transcriptional and chromatin regulation during fasting – The genomic era. Trends Endocrinol. Metab. 2015 Dec;26(12):699-710.
 

More Articles

2017

Isaac R, Goldstein I, Furth N, Zilber N, Streim S, Boura-Halfon S, Elhanany E, Rotter V, Oren M, Zick Y. TM7SF3, a novel p53-regulated homeostatic factor, attenuates cellular stress and the subsequent induction of the unfolded protein response. Cell Death Differ. 2017 Jan;24(1):132-143.

2016

Swinstead EE, Miranda TB, Paakinaho V, Baek S, Goldstein I, Hawkins M, Karpova TS, Ball D, Mazza D, Lavis LD, Grimm JB, Morisaki T, Grøntved L, Presman DM, Hager GL. Steroid Receptors Reprogram FoxA1 Occupancy through Dynamic Chromatin Transitions. Cell. 2016 Apr 21;165(3):593-605.

2014

Charni M, Molchadsky A, Goldstein I, Solomon H, Tal P, Goldfinger N, Yang P, Porat Z, Lozano G, Rotter V. Novel p53 target genes secreted by the liver are involved in non-cell-autonomous regulation. Cell Death Differ. 2016 Mar;23(3):509-20.

 

Shetzer Y, Kagan S, Koifman G, Sarig R, Kogan-Sakin I, Charni M, Kaufman T, Zapatka M, Molchadsky A, Rivlin N, Dinowitz N, Levin S, Landan G, Goldstein I, Goldfinger N, Pe'er D, Radlwimmer B, Lichter P, Rotter V, Aloni-Grinstein R. The onset of p53 loss of heterozygosity is differentially induced in various stem cell types and may involve the loss of either allele. Cell Death Differ. 2014 Sep;21(9):1419-31.

2013

Madar S*, Goldstein I*, Rotter V. 'Cancer associated fibroblasts' - more than meets the eye. Trends Mol Med. 2013 Aug;19(8):447-53.

Madar S, Harel E, Goldstein I, Stein Y, Kogan-Sakin I, Kamer I, Solomon H, Dekel E, Tal P, Goldfinger N, Friedlander G, Rotter V. Mutant p53 attenuates the anti-tumorigenic activity of fibroblasts-secreted interferon beta. PLoS One. 2013 Apr 22;8(4).

Goldstein I, Yizhak K, Madar S, Goldfinger N, Ruppin E, Rotter V. p53 promotes the expression of gluconeogenesis-related genes and enhances hepatic glucose production. Cancer & Metabolism. 2013 Feb 4;1(1):9.

Goldstein I*, Rivlin N*, Shoshana O, Ezra O, Madar S, Goldfinger N, Rotter V. Chemotherapeutic agents activate p53 to induce the transcription of CYP3A genes in the liver – a novel feedback loop for systemic chemotherapy clearance. Carcinogenesis. 2013 Jan;34(1):190-8.

2012

Goldstein I, Rotter V. Regulation of lipid metabolism by p53 – fighting two villains with one sword. Trends Endocrinol. Metab. 2012 Nov;23(11):567-75. 

Kalo E, Kogan-Sakin I, Solomon H, Bar-Nathan E, Shay M, Shetzer Y, Dekel E, Goldfinger N, Buganim Y, Stambolsky P, Goldstein I, Madar S, Rotter V. Mutant p53R273H attenuates the expression of phase 2 detoxifying enzymes and promotes the survival of cells with high ROS levels. J Cell Sci. 2012 Nov 15;125(Pt 22):5578-86.

Solomon H, Buganim Y, Pomeraniec L, Beatus T, Assia Y, Kogan-Sakin I, Madar S, Goldstein I, Brosh R, Kalo E, Goldfinger N, Rotter V. Various p53 mutant types differently regulate the Ras circuit to induce a cancer-related gene signature. J Cell Sci. 2012 Jul 1;125(Pt 13):3144-52.

Goldstein I*, Madar S*, Rotter V. Cancer research, a field on the verge of paradigm shift? Trends Mol. Med., 2012 Jun;18(6):299-303. 

Goldstein I, Ezra O, Rivlin N, Molchadsky A, Madar S, Goldfinger N, Rotter V. p53, a novel regulator of lipid metabolism pathways. J Hepatol. Mar;56(3):656-62. 2012. 

2011

Buganim Y, Madar S, Rais Y, Pomeraniec L, Harel E, Solomon H, Kalo E, Goldstein I, Brosh R, Haimov O, Avivi C, Polak-Charcon S, Goldfinger N, Barshack I, Rotter V. Transcriptional activity of ATF3 in the stromal compartment of tumors promotes cancer progression. Carcinogenesis. 2011 Dec;32(12):1749-57.

Madar S*, Goldstein I*, Rotter V. Beyond tumor suppression: p53 controls blastocyst implantation. Cell Cycle. 2011 Dec 15;10(24):4203. 

Leshem O, Madar S, Kogan-Sakin I, Kamer I, Goldstein I, Brosh R, Cohen Y, Jacob-Hirsch J, Ehrlich M, Ben-Sasson S, Goldfinger N, Loewenthal RC, Gazit E, Rotter V, Berger R. TMPRSS2/ERG promotes epithelial to mesenchymal transition through the ZEB1/ZEB2 axis in a prostate cancer model. PLoS One. 2011 6(7):e21650.

Bornstein C, Brosh R, Molchadsky A, Madar S, Kogan-Sakin I, Goldstein I, Chakravarti D, Flores ER, Goldfinger N, Sarig R, Rotter V. SPATA18, a spermatogenesis-associated gene, is a novel transcriptional target of p53 and p63. Mol Cell Biol. 2011 Apr;31(8):1679-89.

Goldstein I*, Marcel V*, Olivier M, Oren M, Rotter V, Hainaut P. Understanding wild-type and mutant p53 activities in human cancer: new landmarks on the way to targeted therapies. Cancer Gene Ther. 2011 Jan;18(1):2-11. 

2010

Buganim Y, Solomon H, Rais Y, Kistner D, Nachmany I, Brait M, Madar S, Goldstein I, Kalo E, Adam N, Gordin M, Rivlin N, Kogan I, Brosh R, Sefadia-Elad G, Goldfinger N, Sidransky D, Kloog Y, Rotter V. p53 Regulates the Ras circuit to inhibit the expression of a cancer-related gene signature by various molecular pathways. Cancer Res. 2010 Mar 15;70(6):2274-84.

Buganim Y*, Goldstein I*, Lipson D, Milyavsky M, Polak-Charcon S, Mardoukh C, Solomon H, Kalo E, Madar S, Brosh R, Perelman M, Navon R, Goldfinger N, Barshack I, Yakhini Z, Rotter V. A novel translocation breakpoint within the BPTF gene is associated with a pre-malignant phenotype. PLoS One. 2010 Mar 11;5(3):e9657.

2009

Daniel-Carmi V, Makovitzki-Avraham E, Reuven EM, Goldstein I, Zilkha N, Rotter V, Tzehoval E, Eisenbach L. The human 1-8D gene (IFITM2) is a novel p53 independent pro-apoptotic gene. Int J Cancer. 2009 Dec 15;125(12):2810-9.

Goldstein I, Rotter V. Mutations in the tetramerization domain of p53: more than just keeping monomers apart. Cell Cycle. 2009 Oct 15;8(20):3259-60.

S, Goldstein I*, Rotter V. Did experimental biology die? Lessons from 30 years of p53 research. Cancer Res. 2009 Aug 15;69(16):6378-80.

Madar S, Brosh R, Buganim Y, Ezra O, Goldstein I, Solomon H, Kogan I, Goldfinger N, Klocker H, Rotter V. Modulated expression of WFDC1 during carcinogenesis and cellular senescence. Carcinogenesis. 2009 Jan;30(1):20-7.

2008

Brosh R, Shalgi R, Liran A, Landan G, Korotayev K, Nguyen GH, Enerly E, Johnsen H, Buganim Y, Solomon H, Goldstein I, Madar S, Goldfinger N, Børresen-Dale AL, Ginsberg D, Harris CC, Pilpel Y, Oren M, Rotter V. p53-Repressed miRNAs are involved with E2F in a feed-forward loop promoting proliferation. Mol Syst Biol. 2008;4:229.
 

© Designed by HandMed